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Abstract
Background: Gut microbiota composition and function are symbiotically linked with host health and altered in
metabolic, inflammatory and neurodegenerative disorders. Three recognised mechanisms exist by which the
microbiome influences the gut–brain axis: modification of autonomic/sensorimotor connections, immune
activation, and neuroendocrine pathway regulation. We hypothesised interactions between circulating gut-derived
microbial metabolites, and the blood–brain barrier (BBB) also contribute to the gut–brain axis. Propionate, produced
from dietary substrates by colonic bacteria, stimulates intestinal gluconeogenesis and is associated with reduced
stress behaviours, but its potential endocrine role has not been addressed.
Results: After demonstrating expression of the propionate receptor FFAR3 on human brain endothelium, we
examined the impact of a physiologically relevant propionate concentration (1 μM) on BBB properties in vitro.
Propionate inhibited pathways associated with non-specific microbial infections via a CD14-dependent mechanism,
suppressed expression of LRP-1 and protected the BBB from oxidative stress via NRF2 (NFE2L2) signalling.
Conclusions: Together, these results suggest gut-derived microbial metabolites interact with the BBB, representing
a fourth facet of the gut–brain axis that warrants further attention.
Background
The human body plays host to, and exists in symbiosis
with, a significant number of microbial communities,
including those of the skin, the oral and vaginal mucosae
and, most prominently, the gut [1]. This relationship
extends beyond simple commensalism to represent a
major regulatory influence in health and disease, with
changes in abundance of members of the faecal micro-
biota having been associated with numerous pathologies,
including diabetes, hepatic diseases, inflammatory bowel
disease, viral infections and neurodegenerative disorders
[2–8]. Metagenomic studies have revealed reductions in
microbial gene richness and changes in functional cap-
abilities of the faecal microbiota to be signatures of
obesity, liver disease and type II diabetes and that these
can be modified by dietary interventions [9, 10]. The gut
microbiome harbours 150 times more genes than the
human genome, significantly increasing the repertoire of
functional genes available to the host and contributing
to the harvesting of energy from food [11].
The primary form of communication within the gut
microbe–human super-system is metabolic, but our
understanding of the details of the cross-signalling
pathways involved is limited. It is clear, however, that
gut-derived microbial metabolites and products such as
lipopolysaccharide (LPS) can influence human health both
in the intestine and systemically [12, 13], with reported
effects ranging from mediation of xenobiotic toxicity [14],
through modification of the risk of preterm birth [15] to
induction of epigenetic programming in multiple host
tissues [16, 17]. A major aspect of microbe–host systems-
level communication that is receiving increased attention
is the influence the gut microbiota exerts upon the central
nervous system (CNS), the so-called gut–brain axis [18].
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The existence of gut–brain communication is supported
by a number of animal and human studies, although the
underlying mechanisms are not always well defined.
Behavioural analysis of antibiotic-treated or germ-free ro-
dents reveals alterations in both stress responsiveness [19]
and anxiety [20–22], although in germ-free models these
findings are complicated by the life-long absence of
gut microbes and possible consequent developmental
alterations. Nonetheless, gut microbe-depleted animals
have been shown to exhibit changes in serotonergic
and glutamatergic neuronal signalling [20] and expression
of brain-derived neurotrophic factor (BDNF) within the
limbic system [22, 23], providing a molecular correlate for
behavioural changes.
Links between the gut microbiota and brain function
have been identified in studies of humans with autism
spectrum disorders (ASD) and attention-deficit hyper-
activity disorder (ADHD). Altered microbial profiles have
been identified in children with ASD [24–26], and oral
treatment of autistic children with the non-absorbed,
broad-spectrum antibiotic vancomycin—effectively sup-
pressing the gut microbiota—led to a regression in aut-
istic behavioural characteristics that was reversed upon
antibiotic discontinuation [27]. Similarly, a small-scale
intervention study has suggested not only a link be-
tween lower counts of faecal Bifidobacterium species at
6 months and increased incidence of ADHD at 13 years,
but also that early probiotic treatment lessens the risk
of ADHD development [28].
A number of unresolved questions remain as to the
mechanism(s) of communication between the gut micro-
biota and the brain, but three major pathways have been
proposed: direct modification of vagal or sympathetic
sensorimotor function [29], inflammatory/immune activity
[30] and neuroendocrine crosstalk [31]. While research in
this field has focused most heavily on direct neural modu-
lation and inflammatory signalling, the potential role of
circulating gut microbe-derived metabolites has been rela-
tively underexplored. Communication with and across the
blood–brain barrier (BBB), the primary interface between
the circulation and the CNS, may therefore represent a
significant mechanism allowing the gut microbiota to
influence brain function.
There is accumulating evidence that the gut microbiota
can affect the integrity of the BBB, with both broad-
spectrum antibiotic-treated and germ-free mice exhibiting
considerably enhanced barrier permeability and dysregula-
tion of inter-endothelial cell tight junctions [32, 33].
Importantly, these impairments can be reversed upon
conventionalisation. The mechanism(s) by which gut mi-
crobes exert their influence are unclear, but changes to
brain chemistry induced by alteration of the gut micro-
biota can occur independently of vagal or sympathetic
neural pathways and in the absence of any immune
response, strongly suggesting at least a contributory role
for soluble gut-derived microbial metabolites [22].
In particular, data highlight a potential role for short-
chain fatty acids (SCFAs) as key microbial mediators in
the gut–brain axis. SCFAs are principally produced by the
fermentation of complex plant-based polysaccharides by
gut bacteria and are potent bioactive molecules, stimulat-
ing colonic blood flow and upper gut motility, influencing
H2O and NaCl uptake, providing energy for colonocytes,
enhancing satiety and positively influencing metabolic
health in obese and diabetic individuals [34–36]. Of the
SCFAs, acetate is produced in the greatest quantity as a
result of fermentation in the large intestine, followed by
propionate and butyrate [37]. Over 95% of SCFAs pro-
duced are absorbed within the colon with virtually none
appearing in the urine or faeces [35, 38]. However, all
three metabolites are detectable in the peripheral blood of
healthy individuals (http://www.hmdb.ca: acetate, 22–
42 μM; propionate, 0.9–1.2 μM; butyrate, 0.3–1.5 μM).
SCFAs activate members of the free fatty acid receptor
(FFAR) family of G protein coupled receptors; acetate,
propionate and butyrate have affinity in the low millimolar
to high micromolar range for FFAR2; propionate and bu-
tyrate have mid to low micromolar affinity for FFAR3 [39].
The majority of studies looking at the role of SCFAs in
the gut–brain axis have focused on butyrate [40], with
relatively few investigating propionate despite its similar
plasma concentration and receptor affinity. Propionate is
a highly potent FFAR3 agonist for its size (agonist activ-
ity GTPγS pEC50 (Emax) 3.9–5.7(100%)) and is close to
optimal ligand efficiency (−ΔG = 1.26 kcal mol−1 atom−1)
for this receptor [41]. While propionate has been shown
to stimulate intestinal gluconeogenesis through direct
stimulation of enteric–CNS pathways [42] and increased
intestinal propionate has been associated with reduced
stress behaviours [43] and reward pathway activity [44]
in mice and humans, respectively, its potential role as an
endocrine mediator in the gut–brain axis has not been
addressed. Given the presence of FFAR3 on endothelial
cells [45], we hypothesised that propionate targeting of
the endothelium of the BBB would represent an add-
itional facet of the gut–brain axis. We used a systems
approach to test this proposal, performing an unbiased
study of the transcriptomic effects of exposure to
physiological levels of propionate upon the BBB, modelled
by the immortalised human cerebromicrovascular endo-
thelial cell line hCMEC/D3, accompanied by in vitro valid-
ation of identified pathway responses.
Results
Microarray analyses
Following initial confirmation of the expression of FFAR3
in human brain endothelium (Fig. 1a) and on hCMEC/D3
cells (Fig. 1b), we investigated the effect of exposure of
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hCMEC/D3 monolayers to 1 μM propionate for 24 h.
Such treatment had a significant (PFDR < 0.1) effect on the
expression of 1136 genes: 553 upregulated and 583 down-
regulated (Fig. 1c). Initially, we used SPIA with all the sig-
nificantly differentially expressed genes to identify KEGG
signalling pathways inhibited and activated in the presence
of propionate. Protein processing in the endoplasmic
reticulum and RNA transport were activated upon expos-
ure of cells to propionate, which was unsurprising given
gene expression had been induced. A number of path-
ways associated with non-specific microbial infections
(Gram-negative bacteria, viral) were inhibited by propi-
onate (Fig. 1d), as were the cytosolic DNA-sensing




Fig. 1 Effects on gene expression of exposure of the hCMEC/D3 cell line to propionate (1 μM, 24 h). a Representative images of FFAR3
immunoreactivity within endothelial cells of capillaries (i) and larger post-capillary (ii) blood vessels in control human brains post-mortem; scale
bar 20 μm, sections are 5 μm thick; images are representative of five independent cases; areas of particular immunoreactivity are highlighted by
black arrowheads. b Surface expression of FFAR3/GPR41 by hCMEC/D3 cells (grey line, unstained cells, black line secondary antibody control, red
line FFAR3); data are representative of three independent experiments. c Volcano plot showing significantly (PFDR < 0.1, red dots) differentially
expressed genes. The top 20 up- and downregulated genes are labelled. d SPIA evidence plot for the 1136 significantly differentially expressed
genes. Only those human KEGG pathways associated with non-specific microbial infections are labelled. The pathways at the right of the red
oblique line are significant (P < 0.2) after Bonferroni correction of the global P values, pG, obtained by combining the pPERT and pNDE using the
normal inversion method. The pathways at the right of the blue oblique line are significant (P < 0.2) after a FDR correction of the global P values,
pG. 04810. Regulation of actin cytoskeleton (inhibited); 04064, NF-kappa B signalling pathway (inhibited); 04978, mineral absorption (inhibited);
03013, RNA transport (activated); 04141, protein processing in endoplasmic reticulum (activated); 04350, TGF-beta signalling pathway (activated);
04623, cytosolic DNA-sensing pathway (inhibited). e Association of all significantly differentially expressed genes (n = 1136) with KEGG pathways,
Enrichr. f Association of all significantly upregulated genes (n = 553) with WikiPathways, Enrichr. e, f The lighter the colour and the longer the bars,
the more significant the result is. Significance of data was determined using rank-based ranking; only the top 10 results are shown in each case
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infections, triggering innate immune signalling [46]), the
NFκB signalling pathway and the Toll-like receptor signal-
ling pathway. Of the 19,309 genes we examined on the
array, 203 of the 224 genes known to be associated with
the BBB were detected (Additional file 1: Table S1).
Eleven of these were significantly differentially expressed,
with the majority being associated with the inflammatory
response.
Enrichr [47, 48] was used to examine KEGG pathways
significantly associated with the list of significantly
differentially expressed genes. All 1136 significantly dif-
ferentially expressed genes mapped to Enrichr. As with
SPIA, the genes were associated with KEGG pathways
implicated in non-specific microbial infections and RNA-
and endoplasmic reticulum-associated processes (Fig. 1e).
WikiPathways analysis (Enrichr) of all the significantly
differentially expressed genes highlighted responses to oxi-
dative stress being associated with propionate treatment
(not shown). Closer examination of the data demonstrated
this was linked to NRF2 (NFE2L2) signalling, with the
significantly upregulated genes closely associated with
oxidative stress responses (Fig. 1f).
Pathway validation
Transcriptomic analysis identified two particular clusters of
pathways as being regulated by propionate treatment: those
involved in the non-specific inflammatory response to
microbial products (Fig. 1d, e) and those involved in the
response to oxidative stress (Fig. 1f). We, therefore, sought
to validate these responses in an in vitro model of the BBB.
TLR-specific pathway
Inhibition of the TLR-specific pathway by propionate
suggests this metabolite may have a protective role
against exposure of the BBB to bacterial LPS, derived
from the cell walls of Gram-negative bacteria. In accord
with this hypothesis, exposure of hCMEC/D3 mono-
layers for 12 h to propionate at physiological concentra-
tions (1 μM) was able to significantly attenuate the
permeabilising effects of exposure to Escherichia coli
O111:B4 LPS (subsequent 12 h stimulation, 50 ng/ml),
measured both through paracellular permeability to a
70-kDa FITC-conjugated dextran tracer (Fig. 2a) and
trans-endothelial electrical resistance (Fig. 2b). To deter-
mine the specificity of these effects for propionate, we
investigated the actions of the closely related SCFAs
acetate and butyrate. While physiologically relevant
circulating concentrations of butyrate (1 μM) replicated
the effects of propionate on both trans-endothelial elec-
trical resistance and paracellular tracer permeability,
this was not the case for acetate (65 μM) (Fig. 2a, b).
Circulating concentrations of propionate are approxi-
mately 1 μM at rest, but these may be expected to increase
following consumption of, for example, a meal containing
high levels of fermentable fibre [1]; consequently, we exam-
ined the effects of 10 μM and 100 μM propionate upon the
response of hCMEC/D3 monolayers to LPS stimulation.
Both LPS-induced deficits in trans-endothelial electrical
resistance (Additional file 2: Figure S1a) and paracellular
tracer permeability (Additional file 2: Figure S1b) were fully
attenuated by higher doses of propionate, without any
obvious further effects beyond those seen with 1 μM of the
SCFA.
Although hCMEC/D3 cells are a widely used in vitro
model of the BBB, they are not without limitations, par-
ticularly in terms of their higher inherent permeability
when compared with other non-human model systems
[49]. To ensure the validity of our findings using hCMEC/
D3 cells, we repeated these experiments using primary hu-
man brain microvascular endothelial cells (HBMECs). As
with hCMEC/D3 cells, exposure of HBMEC monolayers
for 12 h to propionate (1 μM) significantly attenuated the
permeabilising effects of LPS exposure (subsequent 12 h
stimulation, 50 ng/ml), in terms of both paracellular
permeability to a 70-kDa FITC-conjugated dextran tracer
(Additional file 3: Figure S2a) and trans-endothelial elec-
trical resistance (Additional file 3: Figure S2b). Given this
confirmation, subsequent experiments focused solely on
the hCMEC/D3 cells as an in vitro BBB model.
Paracellular permeability and trans-endothelial elec-
trical resistance are in large part dependent upon the
integrity of inter-endothelial tight junctions [50], which
are known to be disrupted following exposure to LPS
[51]. We, therefore, examined the intracellular distribu-
tion of the key tight junction components occludin,
claudin-5 and zona occludens-1 (ZO-1) following treat-
ment with propionate and/or LPS. Exposure of hCMEC/
D3 monolayers to propionate alone (1 μM, 24 h) had no
noticeable effect on the intracellular distribution of any
of the studied tight junction components, whereas treat-
ment with LPS (50 ng/ml, 12 h) caused a marked disrup-
tion in the localisation of all three major tight junction
molecules, characterised by a loss of peri-membrane im-
munoreactivity (Fig. 2c). Notably, these effects of LPS
were substantially protected against by prior treatment
for 12 h with 1 μM propionate.
LPS initiates a pro-inflammatory response through bind-
ing to Toll-like receptor 4, TLR4, in a complex with
the accessory proteins CD14 and LY96 (MD2) [52];
we, therefore, examined expression of TLR4 signalling
components as an explanation for the protective ef-
fects of propionate upon this pathway. While propi-
onate treatment of hCMEC/D3 cells (1 μM, 24 h) had
no significant effect upon expression of mRNA for TLR4
or LY96 (data not shown), such treatment significantly
downregulated expression of CD14 mRNA (Fig. 2d),
an effect replicated at the level of cell surface CD14
protein expression (Fig. 2e, f ).
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NFE2L2 (NRF2) signalling and protection from oxidative
stress
Enrichr (WikiPathways) analysis indicated that exposure
of hCMEC/D3 cells to propionate resulted in the regula-
tion of a number of antioxidant systems. Of known hu-
man anti-oxidant genes [53], 58 were detected on the
array. We had also identified an additional six genes via
[54] (Additional file 4: Table S2). Searches of the genes as-
sociated with each of the individual pathways referenced
in Fig. 1f strongly indicated these changes occurred down-
stream of the transcription factor nuclear factor, erythroid
2-like 2–NFE2L2 (Fig. 3a). Supporting this analysis, expos-
ure of hCMEC/D3 cells for 24 h to 1 μM propionate





Fig. 2 Protective effects of propionate against LPS-induced barrier disruption. a Assessment of the paracellular permeability of hCMEC/D3
monolayers to 70 kDa FITC–dextran following treatment for 24 h with 65 μM acetate, 1 μM butyrate or 1 μM propionate, with or without
inclusion of 50 ng/ml LPS for the last 12 h of incubation; data are mean ± SEM, n = 3 independent experiments. b Trans-endothelial electrical
resistance of hCMEC/D3 monolayers following treatment for 24 h with 65 μM acetate, 1 μM butyrate or 1 μM propionate, with or without
inclusion of 50 ng/ml LPS for the last 12 h of incubation; data are mean ± SEM, n = 3 independent experiments. c Confocal microscopic analysis
of expression of the tight junction components claudin-5, occludin and zona occludens-1 (ZO-1) in hCMEC/D3 cells following treatment for 24 h
with 1 μM propionate, with or without inclusion of 50 ng/ml LPS for the last 12 h of incubation. Scale bar (10 μm) applies to all images. Images
are representative of at least three independent experiments. d Expression of CD14 mRNA in control and propionate-treated (1 μM; 24 h) hCMEC/
D3 cells according to microarray data (data are mean ± SEM, n = 3). e Surface expression of CD14 protein on control and propionate-treated
hCMEC/D3 cells (grey line, unstained cells, black line secondary antibody control, red line FFAR3); data are representative of three independent
experiments. f Median fluorescence intensity of surface expression of CD14 protein on control and propionate-treated hCMEC/D3 cells; dashed
line indicates isotype control fluorescence intensity; data are mean ± SEM, n = 3 independent experiments
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cytoplasm to the nucleus (Fig. 3b). Functional analysis
of antioxidant pathway activity was assessed by monitor-
ing reactive oxygen species production in hCMEC/D3
cells following exposure to the mitochondrial complex I
inhibitor rotenone (2.5 μM, 2 h). Pre-exposure of cells to
1 μM propionate for 24 h significantly attenuated the rate
of fluorescent tracer accumulation, indicative of reduced
levels of intracellular reactive oxygen species (Fig. 3c).
Efflux transporter expression and activity
A key feature of the BBB is the expression of a wide array
of efflux transporter proteins, which limit entry of numer-
ous endogenous and xenobiotic agents to, and promote
their export from, the brain. Amongst these, the proteins
P-glycoprotein, BCRP and LRP-1 are prominent examples.
We investigated the ability of propionate to both modify
expression of these transporters and, in the case of the
ABC transporter proteins P-glycoprotein and BCRP, serve
as a direct inhibitor or substrate for the protein. Exposure
of hCMEC/D3 monolayers to propionate at physiological
levels (1 μM) for 24 h significantly suppressed expression
of LRP-1 without modulating expression of either BCRP
or P-glycoprotein (Additional file 2: Figure S1a, b).
Similarly, propionate had neither a stimulatory nor
inhibitory effect upon either BCRP or P-glycoprotein
activity, at concentrations between 12 nM and 27 μM
(Additional file 2: Figure S1c–f ).
Discussion
Considerable effort has gone into interrogating the gut–
brain axis over recent years, with a steadily growing
appreciation of the influence of the gut microbiota upon
CNS function in health and disease. Mechanistic studies
have identified three principal aspects to the gut–brain
axis: modification of autonomic sensorimotor connec-
tions [29], immune activation [30] and regulation of
Fig. 3 Protective effects of propionate against oxidative stress. a Representation of stress response genes significantly upregulated in the current
study and directly influenced by NFE2L2, the master regulator of antioxidant responses [54]. b Confocal microscopic analysis of expression of
NFE2L2 (Nrf2) in hCMEC/D3 cells following treatment for 24 h with 1 μM propionate; scale bar (10 μm) applies to all images. Images are
representative of at least three independent experiments. c Production of reactive oxygen species (ROS) in control and propionate pre-treated
(1 μM, 24 h) hCMEC/D3 cells treated for 30 min with the mitochondrial complex I inhibitor rotenone (2.5 μM). Data are mean ± SEM, n = 3
independent experiments
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neuroendocrine pathways [31], all of which incorporate
a role for soluble gut-derived microbial agents, whether
metabolic products or structural microbial components
(e.g. LPS) themselves. In the current study, we identify a
fourth facet to the gut–brain axis, namely, the interac-
tions between gut-derived microbial metabolites and the
primary defensive structure of the brain, the BBB. In
particular, we identify a beneficial, protective effect of
the SCFA propionate upon the BBB, mitigating against
deleterious inflammatory and oxidative stimuli.
If confirmed in vivo, our findings of protective effects of
propionate upon BBB endothelial cells in vitro will add to
the previously described beneficial actions of the SCFA
upon a number of metabolic parameters (Additional file 5).
Propionate has been shown to improve glucose tolerance
and insulin sensitivity, reduce high-density lipoprotein and
increase serum triglyceride concentrations [35, 55, 56], all
of which result in a more stable metabolic homeostasis.
The effects of propionate upon the BBB that we describe
in this study add to these pro-homeostatic actions, empha-
sising the contribution the SCFA plays to maintaining
normal physiological function. Given that the main source
of circulating propionate in humans is the intestinal micro-
biota [57, 58], following fermentation of non-digestible car-
bohydrates by select bacterial species (Fig. 4), propionate
thus represents a paradigm of commensal, mutually benefi-
cial interactions between the host and microbiota. More-
over, consumption of food containing non-digestible
carbohydrates increases circulating propionate concentra-
tions approximately tenfold [59, 60], suggesting that the
anti-inflammatory effects of the SCFA upon the cerebro-
vascular endothelium may be another facet of the known
health benefits of high-fibre diets [61].
That BBB integrity is influenced by the gut microbiota
and that SCFAs may play a role in this process was
recently emphasised in studies of germ-free vs. specific
pathogen-free mice, with germ-free animals exhibiting
enhanced BBB permeability and disrupted cerebral endo-
thelial tight junctions [32]. These permeability defects were
reversed fully upon conventionalisation with a pathogen-
free microbiota and partially with monocultures producing
various SCFAs. Moreover, defective BBB integrity could be
Fig. 4 Production of propionate by the human gut microbiota. Propionate can be produced directly or indirectly by cross-feeding from succinate
and lactate producers (e.g. Selenomonas, Megasphaera and Veillonella spp.). Image produced using information taken from [57]. *Akkermansia
muciniphila is known to produce propionate; it is thought to do this via the succinate pathway [57]
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ameliorated at least partially by extended oral administra-
tion of sodium butyrate. Our findings thus cement SCFAs
as a key group of gut-derived microbial mediators modu-
lating BBB function and provide evidence emphasising a
direct action through the circulation. Propionate acts pri-
marily through either of the two free fatty acid receptors
FFAR2 or FFAR3 [41], which, although absent from neu-
rones in the CNS [62], have been identified in the cerebral
endothelium [45], with FFAR3 confirmed herein, indicating
a possible mechanism of action. Although further study
would be required to prove it conclusively, our data sug-
gest that FFAR3 may be the predominant receptor type
mediating the protective effects of SCFAs. While the major
ligands for this receptor, propionate and butyrate, were
both able to prevent a functional decline in BBB integrity
induced by LPS exposure, this was not the case for acetate,
an SCFA with greater potency at FFAR2 [39]. Future work
investigating the relative contributions of the two receptor
types to BBB integrity will be informative.
Notably, and perhaps unsurprisingly, SCFAs cannot
fully recapitulate the BBB-restoring effects of conventio-
nalisation of germ-free animals, as revealed in the
current work and previously [32, 33]. It, therefore, seems
likely that additional circulating gut-derived microbial
mediators may contribute to the regulation of BBB func-
tion and are thus highly deserving of future investiga-
tion. Given that upwards of 200 distinct microbial
metabolites have been identified in the circulation of
healthy individuals and animals [61, 63], there is clearly
great potential for intestinal dysbiosis and the resultant
variation in metabolite levels to influence the BBB.
This may be highly relevant to the development of
neurological disease, as variation in BBB function is
increasingly recognised to impact on cognitive processes,
although the mechanism(s) underlying this link are poorly
understood. In particular, defects in BBB integrity have
been linked with impaired memory [64] and linguistic [65]
function, as well as with inferior performance on psycho-
metric tests such as the Mini-Mental State Exam [66] and
Oxford Handicap Scale [67]. Antibiotic-induced intestinal
dysbiosis has been associated with similar cognitive defi-
cits and with a reduction in circulating gut-derived micro-
bial metabolites [33], but as yet whether the BBB plays a
role in this connection has not been investigated. If this is
the case, however, as the current study suggests, regula-
tion of BBB function by microbe-derived mediators may
be an important component in some of the emerging links
between intestinal dysbiosis and pathologies as signifi-
cant as depression [68], Parkinson’s disease [69, 70] and
Alzheimer’s disease [71]. Notably, patients with early
Parkinson’s or Alzheimer’s diseases have been shown to
bear reduced levels of Bacteroides species within their
faeces [71, 72]. Given that Bacteroides spp. are important
producers of SCFAs, including propionate [57], from
complex carbohydrates (Fig. 4), this reduction may lead to
a decline in circulating propionate and consequent vulner-
ability of the BBB and, by extension, the brain in these
major neurological conditions.
Modulatory effects of circulating gut-derived microbial
metabolites upon the BBB may also be a component of
the beneficial outcomes seen upon consumption of prebi-
otics or probiotics in a number of neurological conditions.
For example, small-scale clinical trials have identified
beneficial effects of probiotic drinks on cognitive ability in
both Alzheimer’s disease [73] and multiple sclerosis [74],
conditions associated with reduced BBB integrity [75].
Similarly, oral administration of prebiotic oligosaccharides
to mice significantly reduced anxiety and stress behav-
iours, effects that correlated with increases in caecal acet-
ate, propionate and butyrate concentrations [43]. Whether
such changes in caecal SCFA reflected plasma levels were
not measured, but given that SCFAs can be transported
across the gut epithelium [76, 77], increases in circulating
concentrations may be likely. That inflammation contrib-
utes to depression has become clearer over recent years
[78]; hence, it is conceivable that the anti-inflammatory
effects of propionate we describe may underlie at least
part of the protective effects of prebiotic treatment, a pro-
posal which, though speculative, is deserving of further
study.
Conclusions
In summary, we reveal here a significant new aspect of
the gut–brain axis, namely, the modulatory effects of
circulating gut-derived microbial metabolites upon the
endothelium of the BBB. Given the critical gate-keeping
role the BBB plays in communication between the per-
iphery and the brain parenchyma, our findings set the
stage for future investigation of the influence the gut
microbiota has on this structure and the impact intes-
tinal dysbiosis may have upon individual susceptibility to
neurological and psychological diseases.
Methods
Human tissue
Human post-mortem samples were taken from the pre-
frontal cortex from non-neurologic controls; brains were
retrieved from the UK Multiple Sclerosis Society tissue
bank at Imperial College London, under ethical approval
from the UK MRC Brain Bank Network (Ref. No. 08/
MRE09/31+5). Brains were selected according to the
following criteria: (i) availability of full clinical history,
(ii) no evidence of cancer post-mortem and (iii) negli-
gible atherosclerosis of cerebral vasculature. Tissue was
fixed in 10% v/v buffered formalin and embedded in paraf-
fin. From each paraffin block, 5-μm sections were cut and
used for immunohistochemistry for FFAR3 using standard
protocols [79], with a primary rabbit anti-FFAR3
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polyclonal antibody (1:100; Stratech Scientific, Newmar-
ket, UK), a horseradish peroxidase-conjugated goat anti-
rabbit secondary antibody (1:300; Stratech Scientific, UK),
and 2,3-diaminobenzidine and hydrogen peroxide as chro-
mogens. Images were taken using a Leica DM5000 bright-
field microscope equipped with a × 40 oil immersion
objective and analysed using NIH ImageJ 1.51 h (National
Institutes of Health, USA).
Cerebromicrovascular cells
The human cerebromicrovascular endothelial cell line
hCMEC/D3 was purchased from VHBio Ltd (Gateshead,
UK), maintained and treated as described previously
[79–81]. Cells were cultured to confluency in complete
EGM-2 endothelial cell growth medium (Lonza, Basel,
Switzerland), whereupon medium was replaced by
EGM-2 without VEGF and cells were further cultured
for a minimum of 4 days to enable intercellular tight
junction formation prior to experimentation. Primary
human cerebromicrovascular endothelial cells (HBMEC)
were purchased from Sciencell Research Laboratories
(San Diego, CA, USA) and were maintained in ECM
growth medium according to the supplier’s recommen-
dations. Cells were cultured to confluency in complete
ECM (Sciencell Research Laboratories, USA), where-
upon medium was replaced by EGM-2 without VEGF
and cells were further cultured for a minimum of 4 days
to enable intercellular tight junction formation prior to
experimentation. For primary cultures, trans-endothelial
electrical resistance was measured as described below
and experiments were only undertaken when this had
reached approximately 200 Ω cm2.
Microarrays
hCMEC/D3 cells were grown on 6-well plates coated with
calf skin collagen (Sigma-Aldrich, Gillingham, UK) to
confluency as described above, further cultured for 4 days
in EGM-2 medium without VEGF and exposed to propi-
onate (1 μM, 24 h). Cells were collected into TRIzol
(Thermo-Fisher Scientific, UK), and total RNA was ex-
tracted using a TRIzol Plus RNA purification kit (Thermo-
Fisher Scientific, UK) and quantified using an ND-1000
Spectrophotometer (NanoDrop, Wilmington, USA).
Hybridization experiments were performed by Macrogen
Inc. (Seoul, Korea) using Illumina HumanHT-12 v4.0 Ex-
pression BeadChips (Illumina Inc., San Diego, CA). RNA
purity and integrity were evaluated using an ND-1000
Spectrophotometer (NanoDrop, USA) and an Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, USA). Total
RNA was amplified and purified using TargetAmp-Nano
Labelling Kit for Illumina Expression BeadChip (EPI-
CENTRE, Madison, USA) to yield biotinylated cRNA
according to the manufacturer’s instructions. Briefly,
350 ng of total RNA was reverse-transcribed to cDNA
using a T7 oligo(dT) primer. Second-strand cDNA was
synthesised, in vitro-transcribed and labelled with biotin-
NTP. After purification, the cDNA was quantified using
the ND-1000 Spectrophotometer (NanoDrop, USA).
Labelled (750 ng) cDNA samples were hybridised to each
beadchip for 17 h at 58 °C, according to the manufacturer’s
instructions. Detection of array signal was carried out using
Amersham fluorolink streptavidin-Cy3 (GE Healthcare
Bio-Sciences, Little Chalfont, UK) following the bead array
manual. Arrays were scanned with an Illumina bead array
reader confocal scanner according to the manufacturer’s
instructions. The quality of hybridization and overall chip
performance were monitored by visual inspection of both
internal quality control checks and the raw scanned data.
Raw data were extracted using the software provided by
the manufacturer (Illumina GenomeStudio v2011.1, Gene
Expression Module v1.9.0).
Processing and analyses of array data
Raw data supplied by Macrogen were quality-checked,
log2-transformed and loess-normalised (2 iterations) using
affy [82]. Probes annotated as ‘Bad’ or ‘No match’ in
illuminaHumanv4.db [83] were removed from the dataset
(n = 13,631) [84]. After this filtering step, only probes with
valid Entrez identifiers (n = 28,979) were retained for
further analyses. Entrez identifiers were matched to official
gene symbols using ‘Homo_sapiens.gene_info’, down-
loaded from https://www.ncbi.nlm.nih.gov/guide/genes-
expression/ on 14 January 2017. Average gene expression
values were used for identification of differentially
expressed genes. Array data have been deposited in
ArrayExpress under accession number E-MTAB-5686.
Signalling Pathway Impact Analysis (SPIA) was used to
identify Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways activated or inhibited in hCMEC/D3
cells exposed to propionate [85]. Enrichr [47, 48] was used
to confirm KEGG findings (with respect to pathways, not
their activation/inhibition) and to perform Gene Ontology
(GO)- and WikiPathways-based analyses.
In vitro barrier function assessments
Paracellular permeability and trans-endothelial electrical
resistance were measured on 100% confluent cultures
polarised by growth on 24-well plate polyethylene tereph-
thalate (PET) transwell inserts (surface area 0.33 cm2, pore
size 0.4 μm; Appleton Woods, UK) coated with calf skin
collagen and fibronectin (Sigma-Aldrich, UK). The perme-
ability of endothelial cell monolayers to 70 kDa FITC–dex-
tran (2 mg/ml) was measured as described previously [81,
86, 87]; data are presented as the contribution to the
permeability barrier provided by endothelial cells, Pe,
throughout. Trans-endothelial electrical resistance (TEER)
measurements were performed using a Millicell ERS-2 Vol-
tohmmeter (Millipore, Watford, UK) and were expressed as
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Ω cm2. In all cases, values obtained from cell-free inserts
similarly coated with collagen and fibronectin were sub-
tracted from the total values. Briefly, cells were treated with
propionate (1 μM) for 24 h prior to analysis of barrier func-
tion. In some cases, barrier integrity was tested by challenge
with bacterial LPS. Confluent endothelial monolayers were
treated with propionate (1 μM) for 12 h, whereupon LPS
(Escherichia coli O111:B4; 50 ng/ml, comparable to circu-
lating levels of LPS in human endotoxemia [88]) was added
for a further 12 h, without wash-out. Barrier function char-
acteristics were then interrogated as described above.
Efflux transporter assays
Activity of the major efflux transporters P-glycoprotein
and BCRP [89] was determined through the use of
commercially available assays (Solvo Biotechnology Inc.,
Budapest, Hungary), performed according to the manu-
facturer’s instructions. Step-wise dose–response curves
centred around reported physiological circulating con-
centrations of propionate [90] were constructed (n = 2)
and both activating and inhibitory effects of propionate
upon transporter activity were analysed.
Flow cytometry analysis
hCMEC/D3 cells were labelled with APC-conjugated
mouse monoclonal anti-CD14 (Thermo-Fisher Scientific,
Paisley, UK), APC-conjugated mouse monoclonal anti-
BCRP (BD Biosciences, Oxford, UK), FITC-conjugated
mouse monoclonal LRP1 (BD Biosciences, UK), PE-
conjugated mouse monoclonal anti-MDR1A (BD Biosci-
ences, UK), unconjugated rabbit polyclonal antibody
directed against FFAR3/GPR41 (Flarebio Biotech LLC,
College Park, MD, USA) followed by incubation with an
AF488-conjugated goat anti-rabbit secondary antibody
(Thermo-Fisher Scientific, UK) or appropriate isotype
controls (all BD Biosciences, UK) for analysis by flow
cytometry. Briefly, hCMEC/D3 cells were treated for
24 h with propionate (1 μM), detached using 0.05% tryp-
sin and incubated with antibodies as described above.
Immunofluorescence was analysed for 20,000 events per
treatment using a BD FACSCanto II (BD Biosciences,
UK) flow cytometer, and data were analysed using
FlowJo 8.0 software (Treestar Inc., CA, USA).
Immunofluorescence analysis
hCMEC/D3 cells were cultured on Lab-Tek™ Permanox™
8-well chamber slides coated with calf skin collagen
(Sigma-Aldrich, UK), prior to immunostaining according
to standard protocols [79, 81] and using primary anti-
bodies directed against Nrf2 (1:500, Novus Biologicals
Ltd., Abingdon, UK), occludin (1:200, Thermo-Fisher
Scientific, UK), claudin-5 (1:200, Thermo-Fisher Scientific,
UK) and zona occludens-1 (ZO-1; 1:100, Thermo-Fisher
Scientific, UK). Nuclei were counterstained with DAPI
(Sigma-Aldrich, UK). Images were captured using an
LSM880 confocal laser scanning microscope (Carl Zeiss
Ltd., Cambridge, UK) fitted with 405, 488 and 561 nm la-
sers and a × 63 oil immersion objective lens (NA, 1.4 mm,
working distance, 0.17 mm). Images were captured with
ZEN imaging software (Carl Zeiss Ltd., UK) and analysed
using ImageJ 1.51 h (National Institutes of Health, USA).
Statistical analyses
Sample sizes were calculated to detect differences of 15%
or more with a power of 0.85 and α set at 5%, calculations
being informed by previously published data [79, 81]. In
vitro experimental data are expressed as mean ± SEM,
with n = 3 independent experiments performed in tripli-
cate for all studies. In all cases, normality of distribution
was established using the Shapiro–Wilk test, followed by
analysis with two-tailed Student’s t tests to compare two
groups or, for multiple comparison analysis, one- or two-
way ANOVA followed by Tukey’s HSD post hoc test.
Where data was not normally distributed, non-parametric
analysis was performed using the Wilcoxon signed rank
test. A P value of less than or equal to 5% was considered
significant. Differentially expressed genes were identified
in microarray data using LIMMA [91]; P values were cor-
rected for multiple testing using the Benjamini–Hochberg
procedure (false discovery rate); a P value of less than or
equal to 10% was considered significant in this case.
Additional files
Additional file 1: Table S1. Effects of propionate treatment (1 μM, 24 h)
upon mRNA expression of BBB-related genes in hCMEC/D3 cells, grouped in
broad functional categories. Gene names listed in bold were significantly
regulated compared to untreated cells (PFDR < 0.05). (PDF 381 kb)
Additional file 2: Figure S1. Persistence of the protective effect of
propionate upon LPS-induced barrier disruption across different doses. (a)
Assessment of the paracellular permeability of hCMEC/D3 monolayers to
70 kDa FITC–dextran following treatment for 24 h with 1, 10 or 100 μM
propionate, with or without inclusion of 50 ng/ml LPS for the last 12 h of
incubation; data are mean ± SEM, n = 3 independent experiments. (b)
Trans-endothelial electrical resistance of hCMEC/D3 monolayers following
treatment for 24 h with 1, 10 or 100 μM propionate, with or without inclusion
of 50 ng/ml LPS for the last 12 h of incubation; data are mean ± SEM, n = 3
independent experiments. (PDF 341 kb)
Additional file 3: Figure S2. Protective effects of propionate against
LPS-induced barrier disruption in primary human brain microvascular
endothelial cells (HBMEC). (a) Assessment of the paracellular permeability
of HBMEC monolayers to 70 kDa FITC–dextran following treatment for
24 h with 1 μM propionate, with or without inclusion of 50 ng/ml LPS for
the last 12 h of incubation; data are mean ± SEM, n = 3 independent
experiments. (b) Trans-endothelial electrical resistance of HBMEC
monolayers following treatment for 24 h with 1 μM propionate, with or
without inclusion of 50 ng/ml LPS for the last 12 h of incubation; data
are mean ± SEM, n = 3 independent experiments. (PDF 321 kb)
Additional file 4: Table S2. Effects of propionate treatment (1 μM,
24 h) upon mRNA expression of antioxidant system-related genes in
hCMEC/D3 cells. Gene names listed in bold were significantly regulated
compared to untreated cells (PFDR < 0.05). (PDF 385 kb)
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Additional file 5: Figure S3. Effects of propionate upon expression and
activity of typical cerebromicrovascular efflux transporter systems. (a)
Surface expression of BCRP, LRP-1 and P-glycoprotein on control and
propionate-treated (1 μM, 24 h) hCMEC/D3 cells (black, control, red, propionate),
data are representative of three independent experiments. (b) Median
fluorescence intensity of surface expression of BCRP, LRP-1 and P-glycoprotein
on control and propionate-treated (1 μM, 24 h) hCMEC/D3 cells; data are
mean ± SEM, n= 3 independent experiments. (c) Lack of stimulatory effect of
propionate upon BCRP, data are mean ± SEM, n = 4. (d) Lack of inhibitory
effect of propionate upon stimulated ATP-dependent activity of BCRP,
data are mean ± SEM, n = 4. (e) Lack of stimulatory effect of propionate
upon P-glycoprotein, data are mean ± SEM, n = 4. (f) Lack of inhibitory effect
of propionate upon stimulated ATP-dependent activity of P-glycoprotein,
data are mean ± SEM, n = 4. (PDF 437 kb)
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